FROM BUGS TO DRUGS: HARNESSING THE CARDIOPROTECTIVE METABOLOME FOR NEXT-GENERATION CARDIOVASCULAR THERAPEUTICS: A NARRATIVE REVIEW
- St. Georges University,Grenada.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Mater Dei Hospital Malta, Malta.
- Central Park Medical College, Lahore, Pakistan.
- Rangpur Medical college and Hospital, Rangpur Bangladesh.
- North South University , Dhaka Bangladesh.
- Washington University of Health and Science.
- Nishtar Medical University,Multan , Pakistan.
0 Downloads
0 Views
Abstract
Background: Cardiovascular diseases (CVD) remain the primary cause of global mortality, necessitating innovative therapeutic approaches beyond traditional neurohormonal blockade and lipid-lowering therapies. Recent advancements have highlighted the gut microbiota as a dynamic endocrine organ that communicates with the host cardiovascular system via small molecule metabolites. While deleterious metabolites like trimethylamine N-oxide (TMAO) are well-characterized, a distinct panel of commensal-derived cardioprotective metabolites has emerged, presenting new avenues for drug discovery. Objective:This narrative review synthesizes current evidence (2020-2026) regarding the cardioprotective metabolome, exploring the mechanisms by which gut microbial derivatives mitigate atherosclerosis, heart failure, myocardial ischemia reperfusion injury, and metabolic syndrome, while highlighting their transition from preclinical discoveries to clinical therapeutics
How to Cite This Article
Humaira Kousar (2026); FROM BUGS TO DRUGS: HARNESSING THE CARDIOPROTECTIVE METABOLOME FOR NEXT-GENERATION CARDIOVASCULAR THERAPEUTICS: A NARRATIVE REVIEW, Jana Nexus: Journal of Health and Medicine, 2 (08), 24-32, ISSN (O) 3107-7889. DOI: https://doi.org/10.21474/JNHM01/173
Corresponding Author
This work is licensed under a Creative Commons Attribution 4.0 International License.